Berlin, June 15, 2021 ?? European medical cannabis company Cantourage today unveiled its new and innovative platform that enables growers from around the world to bring their product to the growing and profitable European market faster and more cheaply. Cantourage and its partners are already price leaders with a significant market share in the competitive German dronabinol market and now offer products in all relevant market segments ?? Dried flowers, extracts and dronabinol.
“We look forward to expanding our offer with the introduction of our platform, which starts with more than 10 partners from all continents. The current European market is dominated by only a few companies. Newcomers face many hurdles to enter these profitable markets. “We empower farmers and offer them fast, secure European market access while helping them build their brand,” said Philip Schetter, Co-CEO of Cantourage. “Our platform is expanding and improves the offer for patients and healthcare providers in Europe, both in terms of product and price. More importantly, Cantourage guarantees the highest European quality standards for flowers from around the world. We will revolutionize the market. “, Dr. Florian Holzapfel, co-founder of Cantourage, adds.
Cantourage disrupts and breaks through the current market oligopoly by offering cannabis growers worldwide unbureaucratic and fast access to the European market. The company enables growers to sell under their own brands. Through its presence in various segments, Cantourage aims to democratize the market, provide pharmacies and medical cannabis distributors with alternative purchase options across the market, and create new opportunities for the market to grow further. Cantourage is based in Germany, but is already active in four countries across Europe and is set up in such a way that it scales at high speed.
Norman Ruchholtz, Co-CEO at Cantourage said: “The European medical cannabis market is growing the fastest, with over 20 European countries already legalizing medical cannabis and expected sales of over $ 3 billion by 2025. the population is valued as a potential medical cannabis patient, but access to the European market for producers and the supply for patients is still severely limited, as only a few players form a quasi-oligopoly of our customers that this market is ripe for change and disruption. ”
More than 10 breeders from all continents, from Jamaica to Portugal and Uruguay, have already registered as partners and customers, and more are to be added in a few weeks. “Cantourage is one of the few players that can supply the market at high speed while using its existing production and sales networks. Our dried flower product Flos FOTMER T3h is already available in German pharmacies. Together with our investors, we will expand our European presence and reach, to serve additional markets “, explains co-founder Patrick Hoffmann.
The already profitable company recently closed its Series B financing under the direction of longtime partner Think.Health Ventures. In addition to all previous investors, the 10x Group also took part in the financing round, which was valued at a high double-digit million euro amount.
“The management team that leads Cantourage is exceptional. Their over 25 years of experience, their deep understanding of the market, their exceptional setup and their goal of expanding what is available in the market make us very happy to be on board.” explains Dr. Florian Kainzinger, CEO of Think.Health Ventures, who also invested in the medical cannabis sector in 2015 as the first venture capital firm in Germany.
With its market-destroying model and more than 10 supply contracts signed, Cantourage is on the way to becoming one of the European market leaders for medical cannabis.
– Image is available from AP Images (http://www.apimages.com) –
Cantourage is a leading European medical cannabis company. The Berlin company was founded in 2019 by the industry pioneers Dr. Florian Holzapfel, Norman Ruchholtz and Patrick Hoffman founded. Cantourage enables producers from all over the world to bring their products to the growing and profitable European market faster and more cost-effectively while at the same time guaranteeing and further developing the highest European quality standards. It offers products in all relevant market segments: dried flowers, extracts and dronabinol with a strong and growing market share in the latter.